Novel application supports measurable residual
disease (MRD) testing to help monitor cancer and stay ahead of
relapse
BOSTON and ROLLE, Switzerland, June 24,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a global leader in
data-driven medicine, today announced its new Residual Acute
Myeloid (RAM) Application. The new offering expands the company's
comprehensive oncology portfolio to support measurable residual
disease (MRD) capabilities and will be available to customers
worldwide this summer.
Acute Myeloid Leukemia (AML) represents about one percent of all
cancers worldwide, yet is one of the most common forms of leukemia
in adults1. Over 50 percent of AML patients relapse
within 3 years after achieving complete remission2,
therefore post-treatment monitoring is imperative for AML
patients, particularly within the first two years, to help quickly
detect any signs of relapse3. MRD solutions can
help inform post-remission therapy and identify early relapse, and
serve as a primary endpoint in clinical trials, helping researchers
detect even the smallest trace of cancer and support better patient
outcomes.
"AML unfortunately still remains an area of high unmet medical
need today, with associated suboptimal patient outcomes. MRD
measurement and monitoring has a critical role to play, for example
by enabling research into the most optimal sequencing of
therapies," said Philippe Menu, M.D., PhD., Chief Medical Officer
and Chief Product Officer, SOPHiA
GENETICS. "We are proud to contribute to the fight against
AML through our SOPHiA DDM™ RAM Solution. In particular we feel
that the capability to seamlessly track longitudinally the
evolution of individual mutations over time through a dedicated
add-on module of our SOPHiA DDM™ Platform has the potential to be a
game-changer for clinical researchers."
Next-generation sequencing (NGS)-based MRD testing is among the
most advanced in cancer screening and monitoring, and can be found
only with highly sensitive methods. The SOPHiA DDM™ RAM
Solution provides users with the confidence that MRD will detect
even one cancer cell among 10,000 cells. This application will
allow users to stay ahead of disease response with the analytical
capabilities of the SOPHiA DDM™ Platform, enabling sensitive
variant detection down to 0.01% VAF and covering
guideline-recommended genes to deliver robust insights for residual
acute myeloid.
Customers using the SOPHiA DDM™ RAM Solution will have
access to longitudinal variant monitoring, allowing them to
visualize the mutational landscape for each patient and its
evolution over time. The solution also provides users with the most
up-to-date databases and customizable reporting features to
generate graphical representations and comprehensive MRD
reports.
Additionally, the SOPHiA DDM™ RAM Solution will continually hone
its machine learning algorithms to provide the most accurate MRD
results in just four days.
Representatives from SOPHiA GENETICS are available at AMP
(Association for Molecular Pathology) Europe June 24-27 to discuss AML
monitoring with this new application.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.com and connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™ Platform, which analyzes
complex genomic and multimodal data and generates real-time,
actionable insights for a broad global network of hospital,
laboratory, and biopharma institutions. For more information, visit
SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
|
|
|
1 https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html
|
2
www.leukaemiacare.org.uk
|
3
https://onlinelibrary.wiley.com/doi/full/10.1111/apm.12926
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-new-residual-acute-myeloid-ram-application-302179525.html
SOURCE SOPHiA GENETICS